The Effects of Checkpoint Blockade and a CD40 Agonist on T-independent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.35248/2684-1266.16.4.115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant

  2017cited by this paper
• Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

  2017cited by this paper
• Clinical outcomes of patients on check point inhibitor therapy who receive routine vaccinations.

  2017cited by this paper
• Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade.

  2017cited by this paper
• Multiple Myeloma Vaccination Patterns in a Large Health System: A Pilot Study.

  2017cited by this paper
• Clinical and Serologic Responses After a Two‐dose Series of High‐dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single‐arm Trial

  2017cited by this paper
• Targeting Immune Checkpoints in Cancer Therapy.

  2017cited by this paper
• Infections in Cancer Patients with Solid Tumors: A Review

  2017cited by this paper
• Vaccination in Multiple Myeloma: Review of Current Literature.

  2016cited by this paper
• Immune Checkpoint Blockade in Cancer Therapy.

  2015cited by this paper
• Practical review of immunizations in adult patients with cancer

  2015cited by this paper
• Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• CTLA-4 antibodies: new directions, new combinations.

  2014cited by this paper
• Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

  2014cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer

  2009cited by this paper
• T lymphocyte dependence of the antibody response to ‘T lymphocyte independent type 2’ antigens

  2004cited by this paper
• Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma*

  2002cited by this paper
• Up-Regulation of CD40 Ligand and Induction of a Th2 Response in Children Immunized with Pneumococcal Polysaccharide Vaccines

  2001cited by this paper
• Acquired, but Not Innate, Immune Responses to Streptococcus pneumoniae Are Compromised by Neutralization of CD40L

  2000cited by this paper
• Differential Requirement for CD80 and CD80/CD86-Dependent Costimulation in the Lung Immune Response to an Influenza Virus Infection1

  2000cited by this paper
• CD40‐CD40 ligand

  2000cited by this paper
• Enhancement of T cell-independent immune responses in vivo by CD40 antibodies

  1998cited by this paper
• CD40 and CD154 in cell-mediated immunity.

  1998cited by this paper
• Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity.

  1998cited by this paper
• A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens.

  1996cited by this paper
• CD40-CD40 ligand: a multifunctional receptor-ligand pair.

  1996cited by this paper
• T cell-independent antigens type 2.

  1995cited by this paper
• T cell independent antigens.

  1995cited by this paper
• Humoral immune responses in CD40 ligand-deficient mice

  1994cited by this paper
• The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.

  1994cited by this paper
• Immune responses to bacterial polysaccharides: terminal epitopes are more immunogenic than internal structures.

  1994cited by this paper
• gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory

  1994cited by this paper
• In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions

  1993cited by this paper
• Type-specific anti-pneumococcal antibodies in a vaccinated patient with combined immunoglobulin A and IgG2 deficiency and invasive pneumococcal infections.

  1992cited by this paper
• Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

  1987cited by this paper
• Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro.

  1985cited by this paper
• Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae

  1981cited by this paper
• T cell regulation of IgG subclass antibody production in response to T- independent antigens

  1981cited by this paper
• Immunological Aspects of Cancer Chemotherapy

  1980cited by this paper
• Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency

  1980cited by this paper
• Demonstration of two types of helper T cells for different IgG subclass responses to dinitrophenylated flagellin polymer.

  1978cited by this paper
• Subclass restriction of murine anti-carbohydrate antibodies.

  1978cited by this paper
• Programmed Death-1 Ligand 1 Interacts Specifically with the B 7-1 Costimulatory Molecule to Inhibit T Cell Responses

  year unknowncited by this paper

• No citing papers are available for this paper.